Abstract
The enzyme GSK-3 plays a central role in cells during the phosphorylation of various key regulatory proteins, and consequently pharmacological inhibitors of this enzyme potentially allow the treatment of diseases that include neurodegenerative and bipolar affective disorders, diabetes, and diseases caused by unicellular parasites. Today there is a huge number of reported empirical structure-activity relationships (SAR) that may guide a rational design of more potent and selective inhibitors. However, only a few studies based on Quantitative Structure-Activity Relationships (QSAR) are available for predicting the inhibitor potency against this specific kinase, and they involve mainly molecular modeling and 3D-QSAR. The present review deals with the recent search for a quantitative analysis of GSK-3 inhibition.
Keywords: QSAR Theory, Glycogen Synthase Kinase-3, Phosphorylation, CoMFA/CoMSIA, Partial Least Squares, Multivariable Linear Regression, Artificial Neural Network
Medicinal Chemistry
Title: QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3
Volume: 3 Issue: 4
Author(s): Pablo R. Duchowicz and Eduardo A. Castro
Affiliation:
Keywords: QSAR Theory, Glycogen Synthase Kinase-3, Phosphorylation, CoMFA/CoMSIA, Partial Least Squares, Multivariable Linear Regression, Artificial Neural Network
Abstract: The enzyme GSK-3 plays a central role in cells during the phosphorylation of various key regulatory proteins, and consequently pharmacological inhibitors of this enzyme potentially allow the treatment of diseases that include neurodegenerative and bipolar affective disorders, diabetes, and diseases caused by unicellular parasites. Today there is a huge number of reported empirical structure-activity relationships (SAR) that may guide a rational design of more potent and selective inhibitors. However, only a few studies based on Quantitative Structure-Activity Relationships (QSAR) are available for predicting the inhibitor potency against this specific kinase, and they involve mainly molecular modeling and 3D-QSAR. The present review deals with the recent search for a quantitative analysis of GSK-3 inhibition.
Export Options
About this article
Cite this article as:
Pablo R. Duchowicz and Eduardo A. Castro , QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3, Medicinal Chemistry 2007; 3 (4) . https://dx.doi.org/10.2174/157340607781024375
DOI https://dx.doi.org/10.2174/157340607781024375 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Glutamate-regulated Behavior, Transmitter Release, Gene Expression and Addictive Plasticity in the Striatum: Roles of Metabotropic Glutamate Receptors
Current Neuropharmacology Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry Design, Synthesis and Evaluation of the Antidepressant and Anticonvulsant Activities of Triazole-Containing Benzo[d]oxazoles
CNS & Neurological Disorders - Drug Targets Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings
Current Drug Discovery Technologies Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Inflammatory Immunotherapy for Multiple Sclerosis/Experimental Autoimmune Encephalomyelitis (EAE) Disease
Current Medicinal Chemistry Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy
Current Pharmaceutical Design A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Current Drug Abuse Reviews Mitochondrial Diseases in Childhood
Current Molecular Medicine Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Measuring Receptor Occupancy with PET
Current Pharmaceutical Design Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Editorial
Current Medicinal Chemistry